Balyasny Asset Management L.P. Buys Shares of 47,512 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Balyasny Asset Management L.P. purchased a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 47,512 shares of the biotechnology company's stock, valued at approximately $427,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ameriprise Financial Inc. raised its stake in Aurinia Pharmaceuticals by 249.5% during the fourth quarter. Ameriprise Financial Inc. now owns 37,796 shares of the biotechnology company's stock valued at $339,000 after purchasing an additional 26,981 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Aurinia Pharmaceuticals by 5.9% in the 4th quarter. Northern Trust Corp now owns 1,054,365 shares of the biotechnology company's stock valued at $9,468,000 after purchasing an additional 58,676 shares during the last quarter. Quarry LP purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $108,000. Oxford Asset Management LLP bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at approximately $97,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $90,000. Institutional investors own 36.83% of the company's stock.

Insider Transactions at Aurinia Pharmaceuticals

In other news, insider Greg Keenan sold 8,305 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $8.23, for a total transaction of $68,350.15. Following the transaction, the insider now directly owns 153,484 shares in the company, valued at approximately $1,263,173.32. This trade represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joseph M. Miller sold 61,859 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $494,872.00. Following the completion of the transaction, the chief financial officer now directly owns 633,515 shares of the company's stock, valued at $5,068,120. This trade represents a 8.90% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 343,898 shares of company stock valued at $2,753,094. 4.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Trading Up 0.7%

Aurinia Pharmaceuticals stock traded up $0.06 during midday trading on Thursday, reaching $8.40. The stock had a trading volume of 379,381 shares, compared to its average volume of 1,320,584. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -56.16 and a beta of 1.16. Aurinia Pharmaceuticals Inc. has a 52-week low of $5.11 and a 52-week high of $10.67. The company has a fifty day moving average of $8.02 and a 200 day moving average of $8.26.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.08. The firm had revenue of $62.47 million during the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. On average, analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.